ArticleBMC psychiatry2026
Inhibition of the Constructive Aggression Behavioral System (CABS) is associated with poor short- and long-term treatment outcomes and readmission among patients with major depression: a naturalistic study.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Constructive Aggression Behavioral System (CABS) has been conceptualized as an evolutionarily grounded pattern of behavior that enables individuals to assert their needs, interests, and boundaries in a non-violent and socially adaptive manner. It is theoretically distinct from destructive forms of aggression. Inhibition of CABS has been proposed as a clinically relevant construct in emotional disorders. The present study aimed to examine the role of CABS inhibition in treatment outcomes and longer-term prognosis in patients with major depressive disorder (MDD).
methodsA total of 416 inpatients diagnosed with MDD were assessed using the Aggressionshemmungs-Inventar (AHI) to measure CABS inhibition and the revised Beck Depression Inventory (BDI-II) at admission and discharge. Three hierarchical multiple regression analyses were conducted to examine whether AHI scores at discharge were associated with change in depressive symptoms from admission to discharge and whether they predicted depressive symptoms at 6-month follow-up as well as psychiatric readmission within one year. Covariates included age, gender, suicidality, unemployment, comorbid anxiety, and antidepressant use.
resultsAt admission, patients showed elevated AHI scores (mean z = 1.40), indicating substantial inhibition of constructive aggression. During treatment, both depressive symptoms and AHI scores decreased significantly. AHI scores at discharge were associated with symptom change during treatment and with depressive symptoms at 6-month follow-up as well as readmission within one year.
conclusionsThe findings indicate that CABS inhibition represents a clinically relevant correlate of treatment outcome and is associated with follow-up outcomes in MDD. Given the observational design, the results do not allow conclusions regarding causal effects. Future longitudinal and experimental studies are needed to examine whether changes in CABS inhibition are associated with changes in clinical outcomes and to further clarify its potential role in the onset and maintenance of emotional disorders. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.